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Abstract
Background: A small number of patients affected by Neutral Lipid Storage Diseases (NLSDs: NLSD type M with
Myopathy and NLSD type I with Ichthyosis) have been described in various ethnic groups worldwide. However,
relatively little is known about the progression and phenotypic variability of the disease in large specific populations.
The aim of our study was to assess the natural history, disability and genotype-phenotype correlations in Italian
patients with NLSDs. Twenty-one patients who satisfied the criteria for NLSDs were enrolled in a retrospective
cross-sectional study to evaluate the genetic aspects, clinical signs at onset, disability progression and comorbidities
associated with this group of diseases.
Results: During the clinical follow-up (range: 2–44 years, median: 17.8 years), two patients (9.5%, both with NLSD-I)
died of hepatic failure, and a further five (24%) lost their ability to walk or needed help when walking after a mean
period of 30.6 years of disease. None of the patients required mechanical ventilation. No patient required a heart
transplant, one patient with NLSD-M was implanted with a cardioverter defibrillator for severe arrhythmias.
Conclusion: The genotype/phenotype correlation analysis in our population showed that the same gene mutations
were associated with a varying clinical onset and course. This study highlights peculiar aspects of Italian NLSD patients
that differ from those observed in Japanese patients, who were found to be affected by a marked hypertrophic
cardiopathy. Owing to the varying phenotypic expression of the same mutations, it is conceivable that some additional
genetic or epigenetic factors affect the symptoms and progression in this group of diseases.
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Background
The triglycerides (TG) are involved in the synthesis and
degradation pathways of lipids, they are essential for
energy production and for the synthesis of important
cellular structures [1]. The TG not only contribute to
energy production in adipose tissue during fasting, but
also in skeletal muscle during physical exercise. Some
enzymes allow the release of triglycerides from the lipid
droplets in the cytoplasm, two of the most important are
adipose triglyceride lipase (ATGL/PNPLA2, MIM
609059) and comparative gene identification-58 (CGI-
58/ABHD5, MIM 604780) [2, 3]. Inborn errors affecting
ATGL and CGI58 cause two different diseases: Neutral
Lipid Storage Disease with Myopathy (NLSD-M, MIM
610717) and Neutral Lipid Storage Disease with Ichthyosis
(NLSD-I, Chanarin-Dorfman disease, MIM 604780).
Neutral Lipid Storage Diseases (NLSDs) are rare auto-
somal recessive disorders characterized by excessive, non-
lysosomal, accumulation of neutral lipids in multiple
tissues. Clinically NLSDs cause muscle atrophy, cardiomy-
opathy, dysfunction of several internal organs as well as
ichthyosis. The animal model of disease is more severe
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than the human. Structural defects in the PNPLA2 gene
mainly lead to myopathic symptoms, whereas mutations
in the CGI58 gene, the activator of PNPLA2, mainly cause
ichthyosis and hepatic symptoms associated with myo-
pathic symptoms. Although the biochemical basis and
pathogenesis of NLSDs are only partially understood, it is
known that these two enzymes release TG from cytoplas-
mic lipid droplets to supply beta-oxidation in energy
production into mitochondria and to assemble cellular
membranes. Lipid accumulation is present in the skin,
muscle, liver, thyroid, pancreas, heart, central nervous sys-
tem and leukocytes. NLSDs are characterized, among
other things, by lipid-containing vacuoles in white blood
cells (named “Jordans’ anomaly”, from first observer in
1953) [4], which are considered the main diagnostic hall-
mark of NLSDs. Along with important clinical features,
like hepatic steatosis, skeletal myopathy and cardiomyop-
athy, less frequently are present bilateral cataracts, growth
retardation, ataxia, bilateral sensorineural hearing loss and
intellectual disability. Sporadic and familial forms of
NLSDs with a pan-ethnic distribution have been de-
scribed, though detailed descriptions of large numbers of
patients and proper genotype-phenotype relationships are
lacking. The frequency of mutations and the mechanisms
leading to muscle damage also remain largely unknown.
The geographic dispersion of the very small number of
patients and the difficulty of diagnosis further hamper
research in this field. The aim of this study is to create an
Italian registry of NLSD patients to determine their
phenotypes and natural history as well as to investigate
any genetic-phenotypic correlations by collecting clinical
and molecular findings.
Methods
Fourteen centers agreed to take part in this retrospective
study, which started in 2013, during the annual meeting
of the Italian Myology Association. Nine neuromuscular
centres (geographically covering whole Italy) selected
patients of all ages with lipid myopathy from their own
databases. Similar disorders characterized by excessive
lipid storage, i.e. riboflavin-responsive MAD deficiency
due to ETF-dehydrogenase mutations, carnitine disorders
and mitochondrial disorders, were excluded. NLSDs in all
the patients were confirmed by means of genetic tests.
All diagnostic procedures followed the standard prin-
ciples and were approved by the local ethics committees
of all the participating neuromuscular centers in agree-
ment with the Helsinki Declaration of 1975, revised in
2000. The patients gave their informed consent to the
genetic investigation and to the publication of photos.
The following clinical data were analyzed: age, sex, onset
of initial symptoms as reported by patients, signs and
symptoms of muscle weakness and atrophy, daily living
activities, respiratory function evaluated by means of
spirometry and, when possible, the six-minute walking
test, skin, endocrine and cardiac involvement, laboratory
data such as blood tests (CK, serum lipids, glycaemia),
EMG, ECG and Holter ECG, echocardiography, internal
organ ultrasound, respiratory performance and cause of
death. The inclusion criteria were: 1) lipid storage myop-
athy in patients or family members, 2) Jordans’ anomaly,
3) presence of mutations in the PNAPLA2 or CGI58
genes. Genetic analyses were performed in three Italian
centers (Milan, Rome and Pisa). Genomic DNA was
extracted from peripheral blood using a Puregene DNA
Isolation kit (Gentra Systems, Minneapolis). The coding
region of the PNPLA2 gene (GeneBank NM02376) was
amplified using the oligonucleotides and PCR amplifica-
tion conditions previously reported by Tavian et al. [5]. All
CGI58/ABHD5 coding exons (GeneBank NG007090.3)
and the candidate promoter region were PCR amplified.
The conditions for the genomic amplification followed
those described by Redaelli et al. [6]. All PCR products
were gel purified (NucleoSpin Extract II, M-Medical) and
sequenced on 3730 DNA Analyzers by means of the
BigDye® Terminator V1.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA).
To confirm the diagnosis, all the patients were tested
for Jordans’ anomaly using peripheral blood collected by
means of finger or brachial vein puncture; the smeared
slides were then stained using the Giemsa method to
verify the presence of lipid vacuoles in leucocytes by
immersion optic microscopy (100X). Muscle biopsies
were available in 11/15 patients with NLSD-M and 3/6
patients with NLSD-I. The muscle biopsy was not car-
ried out in four NLSD-M patients whose relatives had
already been biopsied and in three patients with NLSD-
I, two of whom mainly displayed hepatic symptoms.
Morphological studies were performed on muscle tissue
obtained by open biopsy: cryosections were stained fol-
lowing standard histochemical and immunohistochemi-
cal procedures.
Patients were examined by means of instrumental and
clinical tests throughout the follow-up period in their
referral neuromuscular centers by neurologists and
cardiologists. All the patients underwent annual clinical
and neurological examination. Muscle strength of the
upper limbs, lower limbs and axial muscles was tested
by means of the Medical Research Council (MRC) scale.
Myalgia, fatigue, swallowing and dysphagia were assessed
by asking patients specific questions on these disorders at
each follow-up visit. At least one EMG/ENG study was
performed in 14 patients with NLSD-M, and in 2 patients
with NLSD-I.
Results
Clinical, genetic and instrumental data were collected
from 21 patients: 15 patients with NLSD-M (9 men and
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6 women, age range: 14–80 year, Table 1) and 6 patients
with NLSD-I (1 man and 5 women, age range: 16–
69 years, Table 2). Patients were followed up for a
mean period of 17.8 years (range: 2–44 years). The
clinical diagnosis was made at an age ranging between
1 and 66 years Most patients originated from regions
in the centre and south of Italy (Lazio, Sardinia,
Molise, Puglia and Sicilia); one patient (pt.V.1) was
born in Iran, but was diagnosed in Italy where she
has been living stably for the past 30 years.
Table 3 shows the results of the age/genotype/clinical
severity correlation analysis in 4 groups of NLSD-M
patients divided according to the degree of muscle
involvement: severe (loss of ambulation, use of wheel-
chair); moderate (interference with daily activities, e.g.
weakness when climbing stairs); mild (muscle weakness
but no interference with daily activities); asymptomatic
(hyperCKemia without symptoms).
The mean delay from the onset of clinical manifesta-
tions to diagnosis was 16.75 years (range 3–32 years) in
patients with NLSD-M and 28 years (range: 1–65 years)
in patients with NLSD-I.
The prognosis was unfavorable in 2 NLSD-I patients,
who died of liver failure at the ages of 69 and 45 years
after unsuccessful liver transplant.
Genetic data
All the Italian families harboring different gene muta-
tions are summarized in Tables 2 and 3, together with
data on the severity of the clinical involvement for each
patient. All homozygous patients were born from
consanguineous parents. We identified 10 different
mutations in 15 NLSD-M patients [5, 7–12], 5 of whom
were homozygous and 10 heterozygous.
Mutations were found to be missense in 6 (55%)
patients, nonsense in 3 (27%) and frameshift variants in
2 (18%). In one, previously described, case (pt.XV.1) no
mutations were detected in either the PNPLA2 or
CGI58 genes [6], but both ichthyosis and Jordans’ anom-
aly were present.
The molecular analysis of CGI58/ABHD5 revealed 4
different mutations in 5 subjects affected by NLSD-I
[6, 13–16]. Two of these variations were nonsense (50%)
while the other 2 were splice-site mutations (50%).
Clinical data
The clinical data are summarized in Tables 1 and 2.
All the patients with NLSD-M had prevalently myo-
pathic symptoms consisting in weakness, which was
accompanied by muscle atrophy in advanced cases. The
onset was mainly asymmetric and in the upper limbs.
The limbs were affected in all the cases, and the axial
muscles, particularly the neck extensors, were also fre-
quently weak and atrophic (Fig. 1a). In the early stages
of disease, the proximal arm and leg muscles were often
involved, while the distal muscles were always clinically
involved in the advanced stages. Muscle weakness repre-
sented the first diagnostic symptom in all the NLSD-M
patients: after a median disease duration of 30.6 years
(15–50 year), 5 of the 21 patients lost their ability to
walk autonomously (pts. I.1, II.1, III.2, V.1 with NLSD-
M and pt. XIII.1 with NLSD-I) and now use assistive
devices (4 are wheelchair-bound and pt. III.2 uses a
walker), while 1 NLSD-M patient displayed difficulties in
climbing stairs (pt. III.1). Fatigue was a constant symp-
tom in all the patients with NLSD-M and in 3 patients
with NLSD-I. Myalgia or cramps were present in 50% of
the NLSD-M patients. Muscle atrophy was present in 8
NLSD-M and 3 NLSD-I patients. None of the 21
patients presented respiratory muscle involvement at the
spirometry or at six-minute walk test (in subjects able to
walk), nor ocular muscle involvement and/or difficulty
in chewing and swallowing. The first sign in patients
with NLSD-I was either liver disease or ichthyosis. The
few asymptomatic patients had hyperCKemia. Ichthyosis
was present in all patients with NLSD-I and transiently
in only one patient with NLSD-M. None of the patients
with NLSDs was obese; indeed, the majority were
slender and only two had a slightly high BMI. Only one
NLSD-I patient was short in stature.
Serum test
Serum creatine kinase (CK) was high in all the NLSD-M
cases and in 2/6 NLSD-I cases (the test was not per-
formed in another 2 patients and was normal in the
remaining 2), with CK levels ranging from 300 to 5700
U/l (average 1000). Routine blood tests showed normal
cholesterol levels in all but 2 NLSD-M patients. Triglyc-
erides were normal in all the patients but 1 with NLSD-I
and 2 with NLSD-M. Mild hyperglycaemia and/or glyco-
suria were found in 4/15 NLSD-M and 1/6 NLDS-I
patients. Jordans’ anomaly, which was tested in all the
patients, was found in 100% of both NLSD-M and
NLSD-I patients (Fig. 1b), and even in one case in which
the genetic tests for PNPLA2 and CGI58/ABHD5 failed
to detect mutations; we had hypothesized the involve-
ment of another undefined gene in the triglyceride path-
way in this last case (pt.XV.1). The percentage of
leukocytes with lipid droplets varied from 10% (pt. IV.1)
to 100% (Table 1), and correlated with disease severity
though not with the patients’ age or disease duration.
Biopsies
Muscle tissue histology in both NLSD-M and NLSD-I
patients revealed mild atrophy and vacuolization of
fibers, though without any increase in connective or
adipose tissue (Fig. 1b).
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Table 3 Clinical-genetic correlation in NLSD-M patients
Family Patient Age at onset Sex and age DNA mutations
in PNPLA2 gene
Protein mutation Mutation effect Clinical severity
Family I I.1 25y F, 69y c.24G > C PT Probably no protein
production
Severe
c.516C > A MM Conserve localization
and partially lipase
function
I.2 40y M, 62y c.24G > C PT Moderate
c.516C > A MM
Family II II.1 47y F, 74y c.24G > C PT Severe
c.516C > A MM
Family III III.1 34y M, 50y c.542delCA TM Loss of hydrophobic
domain
Severe
c.542delCA TM
III.2 35y M, 45y c.542delCA TM Severe
c.542delCA TM
Family IV IV.1 58y F, 74y c.497A > G MM Totally loss of lipase
function
Mild
c.1442C > T MM Partially loss of lipase
function
Family V V.1 52y F, 52y c.659delT D Loss of hydrophobic
domain and
localization
Severe
c.659delT D
Family VI VI.1 1y M, 26y c.41-47del D Probably no protein
production
Moderate
c.41-47del D
Family VII VII.1 40y F, 53y c.553-565del D Loss of hydrophobic
domain
Moderate
c.696 + 4 > G SSM Loss of lipase function
Family VIII VIII.1 40y M, 60y c.177 T > G MM Partially loss of lipase
function
Moderate
c.577A > T MM Partially loss of lipase
function
VIII.2 35y M, 50y c.177 T > G MM Mild
c.577A > T MM
VIII.3 58y F, 58y c.177 T > G MM Mild
c.577A > T MM
Family IX IX.1 64y M, 79y c.570A > C MM Affect central domain Mild
c.570A > C MM
Family X X.1 45y M, 47y c.714C > A MM Unknown Mild
c.714C > A MM
Family XI XI.1 5y M, 14y c.865C > T MM Partially loss of lipase
function
Asymptomatic
c.424A > T PT Loss of hydrophobic
domain
LEGEND: PT protein truncation, MM Missense mutation, TM truncated mutation, D Deletion, DT transcription defect, SSM splice site mutation. Severe: loss of
ambulation, use of wheelchair; Moderate: interference with daily activity; Mild: symptomatic but not interference with daily activity; Asymptomatic: hyperCKemia
without symptoms
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No cellular infiltrates or significant necrosis were de-
tected. Lipid droplets in the cytoplasm of muscle fibers
were detected by means of optic microscopy in 93% of
the muscle biopsies and were positive for O.R.O. stain-
ing. One case with NLSD-M (pt. IV.1 in Table 1) did not
display any significant increase in lipid droplets in
muscle fibers. Two patients also displayed a few ragged
red fibers. A skin biopsy performed in 6 NLSD-M and 2
NLSD-I patients, stained with O.R.O., revealed excessive
lipid droplet storage in all cases.
Electromyographic studies
EMG revealed neurogenic alterations (increased MUP
amplitude, spontaneous activity) in 3/15 NLSD-M pa-
tients, myopathic alterations (motor unit potentials of
reduced amplitude and short duration) in 3/15 NLSD-M
patients, myotonic discharges in 5/15 NLSD-M and 1/6
NLSD-I patients, and mixed pictures (neurogenic/myo-
pathic) in 2/15 NLSD-M and 1/6 NLSD-I patients.
Sensory and motor nerve conduction were normal in all
the patients. Electrophysiological studies were not per-
formed in 4/6 patients with NLSD-I because the patients
were either too young or asymptomatic. The EMG
revealed myotonic discharges in pt. IV.1 [9], in whom
the muscle biopsy was been instead found normal
(Fig. 1d) [14].
Cardiological evaluation
The heart was examined in all the patients in both
groups by means of an echocardiography and ECG;
Holter ECG was also performed in 11 of the 21 patients
(I.1, I.2, II.1, III.1, III.2, IV.1, V.1, VI.1, X.1, XII.1, XII.2)
(Tables 1 and 2). Echocardiography documented cardio-
myopathy with lipid infiltration in 6/15 patients with
NLSD-M and 1/6 with NLSD-I, and was normal in 9/15
patients with NLSD-M. The most common echocardio-
graphic alteration was ventricular hypertrophy. In one
tested patient (III.1) cardiac MRI showed lipid infiltra-
tion; this is the only one patient carrying a defibrillator
for severe arrhythmia.
Eye and audiometric evaluation
A juvenile cataract was observed in 1/6 NLSD-I patients
(XIV.1) and in one adult NLSD-M patient (IV.1).
Deafness was present in only 2 adult NLSD-M patients
(IX.1, XIII.1).
CNS and psychiatric signs
All the patients had attended school and the majority
were able to work. Ten NLSD-M patients (I.1, I.2, III.1,
III.2, IV.1, V.1, VII.1, VIII.1, IX.1, X.1) also underwent a
brain MRI, which revealed mild, non-specific, gliotic
changes. Three patients with NLSD-M had psychiatric
disturbances consisting of anxiety or paranoid personality
(pts. III.1, IV.1, V.1).
One NLSD-M patient had intellectual disability and
behavioral problems (pt. XIII.1). Intellectual disability
was not present in any of our NLSD-I patients.
Discussion
Previous studies on NLSDs have been conducted either on
single cases or on very small cohorts of patients [17–22].
This multicentre study is the most comprehensive study
on a specific population and the longest descriptive study
Fig. 1 Legend: a Weakness and atrophy of proximal and axial muscles in pt. III.1. b Crysection of muscle O.R.O. stained with lipid increase in pt. I.
c Myotonic discharge in patient with NLSD-M in pt. I.2. d Jordans’ anomaly in pt. I.1
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on the natural history of patients with NLSDs. Although
our data are likely to reliably represent the incidence of
NLSD cases in Italy, it is impossible to determine the
prevalence of the disease based on these data because very
mild cases as well as a poor knowledge of this disease may
lead to the disease being underdiagnosed. The difficulties
encountered in making a diagnosis are due to the hetero-
geneous clinical presentation of NLSDs. The delayed diag-
nosis is due both to the lack of knowledge of the disease,
even among experts in neuromuscular disorders, and to
the difficulties in conducting a genetic study. In our experi-
ence, Jordans’ anomaly represents an inexpensive, reliable,
practical biomarker of the disease in both, NLSD type M
and I, as it was found to be present, to varying extents, in
100% of the patients tested.
All the Italian families enrolled in this study harbored
a private mutation, which points to a high probability of
gene mutations and polymorphisms with varying enzym-
atic functional properties [23]. The variability of the
clinical phenotype suggests that the functional study of
the mutations involved in this disease should be encour-
aged to collect information on the activity of the protein
as it may be useful for prognostic purposes [5, 8, 9]. Our
findings show that the spectrum of clinical severity is
wider than previously reported. We identified subjects
with a very late presentation in advanced age as well as
subjects with a severe phenotype under the age of
40 years. We observed that patients diagnosed with
NLSD-M may pass from normal activity to loss of self-
sufficiency within a few years, as demonstrated by three
patients (I.1, III.2 and V.1) in whom the disability
progressed very rapidly, from disease onset to loss of
ambulation and inability to handle objects, over a ten-
year period. Several of our NLSD-M patients also
displayed cardiac involvement, which did not however
generally require therapies other than antihypertensive
treatment, and only in one case a defibrillator for cardiac
arrhythmia. This study suggests that the Italian pheno-
type is different from that observed in subjects from the
Far East [24], in whom cardiac involvement seems to be
the main clinical feature and often leads to heart trans-
plantation. We observed that cardiac involvement in our
patient series is independent of age and disease duration.
The presence of associated features, such as intellectual
disability and deafness, was not significant in our
population.
In our cohort, the prognosis for patients with NLSD
type I appeared to be more severe than that for patients
with NLSD type M. Although life expectancy in our
series of Italian patients with NLSD-M was normal,
there was a significant reduction in the quality of life
owing to motor disabilities in this group, with approxi-
mately one fourth of the cases suffering a loss of ambula-
tion and one patient requiring an electric device. NLSD-I
patients instead had a worse prognosis in terms of life ex-
pectancy, with two deaths due to hepatic failure caused by
lipid infiltration. Although alterations in TG metabolism
caused by ATGL/CGI58 mutations are known to lead to
oxidative metabolism abnormalities [25], the patho-
genesis of muscle damage in NLSDs has not yet been
fully understood. In effect, muscle atrophy, present
even in the early stages of disease, cannot be as-
cribed exclusively to metabolic defects. Unlike leuko-
cytes, in which the proportion of lipids correlates
with the severity of the disease, muscle lipid accumu-
lation does not always correlate with the motor
impairment. Indeed, as reported previously by other
authors [12, 26, 27], we had patients (XI, XII.1,
XII.2), with high lipid storage in muscle who were
asymptomatic. Only one of our patients (IV.1), who
did not have a significant accumulation of lipids in
muscle, displayed EMG abnormalities, mild hyperCK-
emia, weakness and fatigability in the absence of
atrophy.
The correlation between the phenotype and genotype
in NLSDs cannot be easily investigated.
The number of patients with NLSD-I was too small
for conclusive results about phenotype/genotype correl-
ation (Table 2). A recent Turkish report on this question
failed to detect any meaningful correlations [28]. In
NLSD-M, an evaluation of residual enzymatic activity in
vitro can predict the type of mutation and provides gen-
eral information on the severity of the disease. Neverthe-
less, we observed that there was a marked variability in
disease expression even within the same family (see fam-
ilies III and VIII), which contained younger members
who were unexpectedly affected largely than their older
siblings.
Conclusions
The severity of the clinical involvement in NLSD-M
seems to depend partially on the type of mutation and
on residual enzymatic activity, as reported in a previous
study [20]. The same mutation in our cohort was found
to result in different phenotypes; it is conceivable that
epigenetic factors, such as the environment and lifestyle,
which are known to affect muscle activity, and diet (e.g.
containing varying amounts of different types of lipids),
may also play an important role. We cannot rule out the
possibility that other genes involved in the complex
system of lipid metabolism also affect disease expression
in NLSD-M. This study provides valuable information
on the prognosis in this group of diseases, which may be
used to counsel patients and improve the management
and standards of care.
Lastly, we provide data on the progression of such
diseases, which might be crucial for planning future
clinical and therapeutic trials.
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